7713.TWO WeLeader Biomedical Co., Ltd.
- Market cap
- TWD 3.21B
- P/E
- 14.0x
- P/B
- 2.67x
- ROE
- 21.9%
- Dividend yield
- 4.78%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 7713.TWO undervalued?
Graham number7713.TWO trades 28.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
WeLeader Biomedical Co., Ltd. fundamental analysis
No fundamental analysis for WeLeader Biomedical Co., Ltd. yet.
WeLeader Biomedical Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About WeLeader Biomedical Co., Ltd.
WeLeader Biomedical Co., Ltd. operates as an agent and distributor of in vitro diagnostic products. It offers a range of medical testing systems, such as serum biochemistry integration platform, clinical care, and medical information integration system. The company also provides blood gas electrolyte analyzers, urine analyzers, integrated fully automatic biochemical analyzers, fully automatic electronic luminescence immunoassay products, fully automatic modular biochemical i…
Full company profileWeLeader Biomedical Co., Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
WeLeader Biomedical Co., Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 841M | 1.04B | 941M | 991M | 1.11B | 1.24B |
| Gross Profit | 219M | 292M | 298M | 316M | 371M | 439M |
| Operating Income | 133M | 194M | 197M | 214M | 261M | 322M |
| EBITDA | - | 307M | 303M | 330M | 393M | 479M |
| Net Income | 106M | 154M | 152M | 170M | 209M | 263M |
| EPS | 2.54 | 3.70 | 3.66 | 4.09 | 4.59 | 5.79 |
| Balance Sheet | ||||||
| Total Assets | 883M | 1.60B | 1.73B | 2.00B | 2.45B | 2.52B |
| Total Liabilities | 526M | 954M | 882M | 1.09B | 1.19B | 1.32B |
| Shareholders' Equity | 357M | 646M | 846M | 908M | 1.26B | 1.20B |
| Cash & Short-term Investments | 112M | 101M | 94.7M | 175M | 238M | 90.3M |
| Cash Flow | ||||||
| Operating Cash Flow | 238M | 280M | 232M | 279M | 313M | 297M |
| Capital Expenditure | 23.9M | 662M | 116M | 174M | 214M | 65.6M |
| Free Cash Flow | 214M | -381M | 116M | 104M | 99.6M | 231M |
| Ratios | ||||||
| ROE | 29.6% | 23.8% | 18.0% | 18.7% | 16.6% | 21.9% |
| ROA | 12.0% | 9.6% | 8.8% | 8.5% | 8.5% | 10.4% |
| Net Profit Margin | 12.6% | 14.8% | 16.2% | 17.2% | 18.8% | 21.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
WeLeader Biomedical Co., Ltd. dividends
- Dividend yield
- 4.78%
- Forward dividend
- 4.10 TWD
- Payout ratio
- 73.4%
- Ex-dividend date
- Mar 27, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 153M | 3.37 | 73.4% |
| 2024 | TWD 95.6M | 2.30 | 56.2% |
| 2023 | TWD 29.8M | 0.72 | 19.5% |
| 2022 | TWD 9.77M | 0.23 | 6.4% |
| 2021 | TWD 22.4M | 0.54 | 21.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns WeLeader Biomedical Co., Ltd.
- Insiders 82.67%
- Institutions 0.00%
- Public & others 17.33%
- Shares outstanding 45.5M
- Free float 8.14M
WeLeader Biomedical Co., Ltd. company profile
- Company name
- WeLeader Biomedical Co., Ltd.
- Ticker
- 7713.TWO
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Medical Devices
- Fiscal year end
- December
- Address
- No. 80, Minzu 1st Road, Kaohsiung, Taiwan
- Phone
- 886 7 380 0773
- Website
- weleader.com.tw
About WeLeader Biomedical Co., Ltd.
WeLeader Biomedical Co., Ltd. operates as an agent and distributor of in vitro diagnostic products. It offers a range of medical testing systems, such as serum biochemistry integration platform, clinical care, and medical information integration system. The company also provides blood gas electrolyte analyzers, urine analyzers, integrated fully automatic biochemical analyzers, fully automatic electronic luminescence immunoassay products, fully automatic modular biochemical immune assay products, TTA automated pre-processing products, POCT central laboratory products, and CCM fully automated track processing products. It serves research institutions, schools, hospitals, laboratories, and hospitals. The company was founded in 1992 and is headquartered in Kaohsiung, Taiwan.
WeLeader Biomedical Co., Ltd. management
2- Chen Hung-JenPresident
- Lo Chun-IAccounting Manager